A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer

Aruna Mani, Sandra X. Franco, Grace Wang, Neil Abramson, Lee S. Schwartzberg, James W Jakub, Elizabeth Tan-Chiu, Michael A. Schwartz, Cynthia Frankel, Elisa A. Krill-Jackson, Alisha Stein, Alejandra T. Perez, Charles L. Vogel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89% of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2%) and leukopenia (8%). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15%) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalCommunity Oncology
Volume8
Issue number5
StatePublished - May 2011

Fingerprint

docetaxel
Carboplatin
Breast Neoplasms
Drug Therapy
Leukopenia
Area Under Curve
Fever
Capecitabine

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Mani, A., Franco, S. X., Wang, G., Abramson, N., Schwartzberg, L. S., Jakub, J. W., ... Vogel, C. L. (2011). A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. Community Oncology, 8(5), 209-215.

A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. / Mani, Aruna; Franco, Sandra X.; Wang, Grace; Abramson, Neil; Schwartzberg, Lee S.; Jakub, James W; Tan-Chiu, Elizabeth; Schwartz, Michael A.; Frankel, Cynthia; Krill-Jackson, Elisa A.; Stein, Alisha; Perez, Alejandra T.; Vogel, Charles L.

In: Community Oncology, Vol. 8, No. 5, 05.2011, p. 209-215.

Research output: Contribution to journalArticle

Mani, A, Franco, SX, Wang, G, Abramson, N, Schwartzberg, LS, Jakub, JW, Tan-Chiu, E, Schwartz, MA, Frankel, C, Krill-Jackson, EA, Stein, A, Perez, AT & Vogel, CL 2011, 'A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer', Community Oncology, vol. 8, no. 5, pp. 209-215.
Mani, Aruna ; Franco, Sandra X. ; Wang, Grace ; Abramson, Neil ; Schwartzberg, Lee S. ; Jakub, James W ; Tan-Chiu, Elizabeth ; Schwartz, Michael A. ; Frankel, Cynthia ; Krill-Jackson, Elisa A. ; Stein, Alisha ; Perez, Alejandra T. ; Vogel, Charles L. / A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. In: Community Oncology. 2011 ; Vol. 8, No. 5. pp. 209-215.
@article{2d9a2d5c96f6467d9f34335e7934ce4d,
title = "A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer",
abstract = "This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89{\%} of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2{\%}) and leukopenia (8{\%}). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15{\%}) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.",
author = "Aruna Mani and Franco, {Sandra X.} and Grace Wang and Neil Abramson and Schwartzberg, {Lee S.} and Jakub, {James W} and Elizabeth Tan-Chiu and Schwartz, {Michael A.} and Cynthia Frankel and Krill-Jackson, {Elisa A.} and Alisha Stein and Perez, {Alejandra T.} and Vogel, {Charles L.}",
year = "2011",
month = "5",
language = "English (US)",
volume = "8",
pages = "209--215",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "5",

}

TY - JOUR

T1 - A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer

AU - Mani, Aruna

AU - Franco, Sandra X.

AU - Wang, Grace

AU - Abramson, Neil

AU - Schwartzberg, Lee S.

AU - Jakub, James W

AU - Tan-Chiu, Elizabeth

AU - Schwartz, Michael A.

AU - Frankel, Cynthia

AU - Krill-Jackson, Elisa A.

AU - Stein, Alisha

AU - Perez, Alejandra T.

AU - Vogel, Charles L.

PY - 2011/5

Y1 - 2011/5

N2 - This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89% of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2%) and leukopenia (8%). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15%) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.

AB - This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapy in locally advanced breast cancer with four 28-day cycles of dose-dense chemotherapy: weekly docetaxel (30 mg/m2) and carboplatin (AUC 2) on days 1, 8, and 15, plus capecitabine (625 mg/m2) twice daily on days 5-18. The primary endpoint was pathologic complete response (pCR). Among the 49 treated patients, 89% of intended chemotherapy doses (including capecitabine) were administered. In the intent-to-treat patients, grade 4 toxicities were depression (2%) and leukopenia (8%). There were no neutropenic fevers or treatment-related deaths. Of the 41 evaluable patients who received all four chemotherapy cycles, 6 (15%) achieved a pCR; all of them had negative axillary nodes. None of the patients with pCR had developed recurrent disease at a median follow-up of 48 months. We conclude that preoperative docetaxel, carboplatin, and capecitabine has an acceptable toxicity profile and a pCR rate comparable with that seen in many other phase II neoadjuvant chemothera.

UR - http://www.scopus.com/inward/record.url?scp=79958818349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958818349&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79958818349

VL - 8

SP - 209

EP - 215

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 5

ER -